Profile | GDS2987 / GI_10864034-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | ||
GSM215244 | HMVEC_vehicle_rep2 | 10.3 | 27 |
GSM215253 | HMVEC_vehicle_rep3 | 14.3 | 43 |
GSM215254 | HMVEC_atorvastatin_rep1 | 19.2 | 45 |
GSM215282 | HMVEC_atorvastatin_rep3 | 32.6 | 58 |
GSM215344 | HMVEC_atorvastatin_rep2 | 8.7 | 22 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 13.2 | 26 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 42.7 | 56 |
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | 15.1 | 30 |
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 22.6 | 34 |
GSM215298 | PASMC_vehicle_rep2 | 1.6 | 3 |
GSM215310 | PASMC_vehicle_rep3 | 7.1 | 12 |
GSM215311 | PASMC_atorvastatin_rep1 | 65.2 | 69 |
GSM215312 | PASMC_atorvastatin_rep2 | 5.7 | 9 |
GSM215313 | PASMC_atorvastatin_rep3 | 38.5 | 50 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 67 | 68 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 6.6 | 13 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 18.2 | 30 |
GSM215327 | PASMC_SLx2119_rep1 | 46.8 | 60 |
GSM215328 | PASMC_SLx2119_rep2 | 24.1 | 41 |
GSM215329 | PASMC_SLx2119_rep3 | 29.6 | 49 |
GSM215330 | Fibroblasts_vehicle_rep1 | 18.3 | 39 |
GSM215331 | Fibroblasts_vehicle_rep2 | 22.2 | 51 |
GSM215332 | Fibroblasts_vehicle_rep3 | ||
GSM215333 | Fibroblasts_atorvastatin_rep1 | 22.3 | 50 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 9.5 | 27 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 26.4 | 53 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 19.1 | 52 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 15.5 | 44 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 23.5 | 53 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 23 | 54 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 11.1 | 31 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 19.8 | 45 |